Amyloidogenic medin induces endothelial dysfunction and vascular inflammation through the receptor for advanced glycation endproducts
Author
Migrino, Raymond Q.Davies, Hannah A.
Truran, Seth
Karamanova, Nina
Franco, Daniel A.
Beach, Thomas G.
Serrano, Geidy E.
Truong, Danh
Nikkhah, Mehdi
Madine, Jillian
Affiliation
Univ Arizona, Coll Med Phoenix, Dept MedIssue Date
2017-09-01
Metadata
Show full item recordPublisher
OXFORD UNIV PRESSCitation
Raymond Q. Migrino, Hannah A. Davies, Seth Truran, Nina Karamanova, Daniel A. Franco, Thomas G. Beach, Geidy E. Serrano, Danh Truong, Mehdi Nikkhah, Jillian Madine, Amyloidogenic medin induces endothelial dysfunction and vascular inflammation through the receptor for advanced glycation endproducts, Cardiovascular Research, Volume 113, Issue 11, September 2017, Pages 1389–1402, https://doi.org/10.1093/cvr/cvx135Journal
CARDIOVASCULAR RESEARCHRights
Published by Oxford University Press on behalf of the European Society of Cardiology 2017. This work is written by US Government employees and is in the public domain in the US.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Aims Medin is a common amyloidogenic protein in humans that accumulates in arteries with advanced age and has been implicated in vascular degeneration. Medin's effect on endothelial function remains unknown. The aims are to assess medin's effects on human arteriole endothelial function and identify potential mechanisms underlying medin-induced vascular injury. Methods and results Ex vivo human adipose and leptomeningeal arterioles were exposed (1 h) to medin (0.1, 1, or 5 mu M) without or with FPS-ZM1 [100 mu M, receptor for advanced glycation endproducts (RAGE)-specific inhibitor] and endothelium-dependent function (acetylcholine dilator response) and endothelium-independent function (dilator response to nitric oxide donor diethylenetriamine NONOate) were compared with baseline control. Human umbilical vein endothelial cells were exposed to medin without or with FPS-ZM1 and oxidative and nitrative stress, cell viability, and pro-inflammatory signaling measures were obtained. Medin caused impaired endothelial function (vs. baseline response: -45.2 +/- 5.1 and -35.8 +/- 7.9% in adipose and leptomeningeal arterioles, respectively, each P < 0.05). Dilator response to NONOate was not significantly changed. Medin decreased arteriole and endothelial cell nitric oxide production, increased superoxide production, reduced endothelial cell viability, proliferation, and migration. Medin increased gene and protein expression of interleukin-6 and interleukin-8 via activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF kappa B). Medin-induced endothelial dysfunction and oxidative stress were reversed by antioxidant polyethylene glycol superoxide dismutase and by RAGE inhibitor FPS-ZM1. Conclusions Medin causes human microvascular endothelial dysfunction through oxidative and nitrative stress and promotes pro-inflammatory signaling in endothelial cells. These effects appear to be mediated via RAGE. The findings represent a potential novel mechanism of vascular injury.Note
Public domain articleISSN
0008-63631755-3245
Version
Final published versionSponsors
Veterans Affairs Merit grant [BX-003767-01, BX007080]; National Institutes Health [NIA R21AG044723, NINDS U24NS072026, NIA P30AG19610, NIA RO1AG019795]; British Heart Foundation [FS/12/61/29877]; Arizona Department of Health Services [211002]; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research and Amyloidosis Foundation; Department of Veterans Affairs and VA employmentAdditional Links
http://academic.oup.com/cardiovascres/article/113/11/1389/3979882/Amyloidogenic-medin-induces-endothelialae974a485f413a2113503eed53cd6c53
10.1093/cvr/cvx135
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Published by Oxford University Press on behalf of the European Society of Cardiology 2017. This work is written by US Government employees and is in the public domain in the US.